drugset / Trial / NCT03511378
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the immunogenicity of Peg-filgrastim versus Neulasta® as an adjunct to chemotherapy in patients with breast cancer
Timeline
- Start
- 2018-03-06
- Primary completion
- 2019-01-09
- Completion
- 2019-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |